These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38902191)

  • 21. Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study.
    Yun B; Park H; Ahn SH; Oh J; Kim BK; Yoon JH
    Am J Gastroenterol; 2024 Jun; ():. PubMed ID: 38934496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study.
    Park Y; Jung J; Han S; Kim GA
    Aliment Pharmacol Ther; 2024 Sep; ():. PubMed ID: 39304991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study.
    Mayén AL; Sabra M; Aglago EK; Perlemuter G; Voican C; Ramos I; Debras C; Blanco J; Viallon V; Ferrari P; Olsen A; Tjønneland A; Langmann F; Dahm CC; Rothwell J; Laouali N; Marques C; Schulze MB; Katzke V; Kaaks R; Palli D; Macciotta A; Panico S; Tumino R; Agnoli C; Farràs M; Molina-Montes E; Amiano P; Chirlaque MD; Castilla J; Werner M; Bodén S; Heath AK; Tsilidis K; Aune D; Weiderpass E; Freisling H; Gunter MJ; Jenab M
    BMC Med; 2024 Jun; 22(1):221. PubMed ID: 38825687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study.
    Kim GA; Jeong S; Jang H; Lee DH; Joo SK; Kim W
    Liver Cancer; 2024 Aug; 13(4):426-437. PubMed ID: 39114758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period.
    Mori K; Tanaka M; Sato T; Akiyama Y; Endo K; Ogawa T; Suzuki T; Aida H; Kawaharata W; Nakata K; Hosaka I; Umetsu A; Hanawa N; Furuhashi M
    Hepatol Res; 2024 Aug; ():. PubMed ID: 39110552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
    Kalligeros M; Vassilopoulos A; Vassilopoulos S; Victor DW; Mylonakis E; Noureddin M
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1330-1332.e4. PubMed ID: 37949334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
    Moon JH; Jeong S; Jang H; Koo BK; Kim W
    EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
    Mori K; Akiyama Y; Tanaka M; Sato T; Endo K; Hosaka I; Hanawa N; Sakamoto N; Furuhashi M
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1382-1393. PubMed ID: 38629681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
    Ochoa-Allemant P; Marrero JA; Serper M
    Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The systemic inflammation response index as a risk factor for hepatic fibrosis and long-term mortality among individuals with metabolic dysfunction-associated steatotic liver disease.
    Yin Y; Zhu W; Xu Q
    Nutr Metab Cardiovasc Dis; 2024 Aug; 34(8):1922-1931. PubMed ID: 38866613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.
    Canivet CM; Boursier J; Loomba R
    Semin Liver Dis; 2024 Feb; 44(1):35-42. PubMed ID: 38531378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic characteristics of patients with MetALD: Caveats of a new definition.
    Petrie E; Gray M; Bril F
    Liver Int; 2024 Aug; ():. PubMed ID: 39152688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
    Song R; Li Z; Zhang Y; Tan J; Chen Z
    Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of healthy lifestyles with risk of all-cause and cause-specific mortality among individuals with metabolic dysfunction-associated steatotic liver disease: results from the DFTJ cohort.
    Deng Q; Zhang Y; Guan X; Wang C; Guo H
    Ann Med; 2024 Dec; 56(1):2398724. PubMed ID: 39247937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.
    Younossi ZM; Stepanova M; Ong J; Yilmaz Y; Duseja A; Eguchi Y; El Kassas M; Castellanos-Fernandez M; George J; Jacobson IM; Bugianesi E; Wong VW; Arrese M; de Ledinghen V; Romero-Gomez M; Mendez-Sanchez N; Ahmed A; Wong R; Papatheodoridis G; Serfaty L; Younossi I; Nader F; Ziayee M; Afendy A;
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1625-1633.e1. PubMed ID: 30476585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between Alcohol Consumption and Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Alcohol Flushing Response in Men: The Korea National Health and Nutrition Examination Survey 2019-2021.
    Kang DE; Oh SN
    Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature.
    Ma N; Bansal M; Chu J; Branch AD
    J Pediatr Gastroenterol Nutr; 2024 Aug; 79(2):229-237. PubMed ID: 38693784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
    Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
    Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.